Taysha Completes BLA-Enabling TSHA-102 Manufacturing Campaign

The Tip Desk · November 12, 2026 · 3 min read

The company finished a PPQ run that met product and comparability criteria and said cash of $422.8 million funds operations into the second half of 2028.

Taysha Gene Therapies, Inc. (TSHA), a clinical-stage biotechnology company developing adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system, completed its Biologics License Application-enabling process performance qualification manufacturing campaign for TSHA-102, its investigational gene therapy for Rett syndrome.

The company said the campaign produced commercial-scale drug product batches required to validate the final commercial manufacturing process in support of a potential BLA submission and future commercialization. All process parameters and analytical results met predefined product specifications and comparability criteria for commercial product and clinical material. Together with comparability of clinical material used across REVEAL Part A and Part B, those results support potential inclusion of REVEAL Part A Phase 1/2 data in the planned BLA.

The final manufacturing process consistently achieved a single-digit empty capsid percentage, which the company described as an important indicator of product quality that contributes to patient safety. Taysha said the PPQ results also demonstrate process consistency and scalability required to support potential commercial demand. It plans to discuss the chemistry, manufacturing and controls data in an anticipated FDA Type B meeting in the fourth quarter of 2026, with FDA feedback expected in the first quarter of 2027.

Clinical work on TSHA-102 continued. High-dose and low-dose treatments remained generally well tolerated, with no severe treatment-related serious adverse events or dose-limiting toxicities across the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff. All patients in those studies had cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies.

Chairman and Chief Executive Officer Sean P. Nolan said the company’s focus now turns to delivering a robust dataset to support the planned BLA submission. Taysha reiterated that it expects to report topline data from the REVEAL pivotal trial’s six-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027. The company also said it expects to nominate an additional gene therapy development candidate targeting a CNS disorder with high unmet need and commence preclinical development in the first half of 2027.

Research and development expenses were $28.8 million for the three months ended September 30, 2026, compared with $25.7 million a year earlier. The company said the $3.1 million increase was primarily driven by higher clinical expenses from the REVEAL Part A Phase 1/2, REVEAL Part B pivotal and ASPIRE trials, as well as higher compensation including non-cash stock-based compensation from additional research and development headcount.

General and administrative expenses were $13.1 million for the three months ended September 30, 2026, compared with $8.3 million a year earlier. The company attributed the $4.8 million increase primarily to higher compensation including non-cash stock-based compensation and increases in consulting and professional fees, including commercial launch-readiness initiatives.

Net loss was $39.1 million, or $0.10 a share, for the three months ended September 30, 2026, compared with a net loss of $32.7 million, or $0.09 a share, a year earlier. Revenue remained $0 for the quarter.

Cash and cash equivalents were $422.8 million as of September 30, 2026. The company said it expects current cash resources to support planned operating expenses and capital requirements into the second half of 2028.

TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy designed as a one-time treatment that aims to deliver a functional form of MECP2 to cells in the CNS. It has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA.